Rheumatic/Immunologic/Autoimmune Diseases
At a glance...
Rheumatoid Arthritis
Other
|
Publications
“Tocilizumab inhibits structural joint damage in RA patients with an inadequate response to methotrexate at 1 year: the LITHE study” (clinical trial) “Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment” (review) “Optimizing outcomes in rheumatoid arthritis patients with inadequate response to disease-modifying antirheumatic drugs” (review) “Everolimus in patients with rheumatoid arthritis receiving concomitant methotrexate: a 3-month, randomized, double-blind, placebo-controlled, parallel-group, proof-of-concept study” (clinical trial) "Ensuring appropriate treatment in rheumatoid arthritis: biologic therapies in perspective” (review) “Baseline determinants of tumor necrosis factor-α inhibitor switching in patients with rheumatoid arthritis” (poster) “Long-term safety and tolerability of tocilizumab in patients with a mean treatment duration of 1.5 years” (poster) “Sulfasalazine versus diclofenac in the early treatment of rheumatoid arthritis” (clinical study report) “Modulation of mononuclear cell functions by cryofiltration in rheumatoid arthritis” (preclinical research) "Immunization with CDR peptides generates antiidiotypic antibodies specific for therapeutic human antibodies" (preclinical research) “Update on the risk-benefit profile of infliximab in the treatment of Crohn’s disease” (meeting report) Monograph for a commercial assay measuring anti-human antibodies to anti-TNF agents Research grants and scientific presentations on immune function, cells, and cytokines/inflammatory mediators in rheumatoid arthritis, systemic lupus erythematosus, scleroderma, and polymyositis |